✦ LIBER ✦

Discontinuation of ropinirole and pramipexole in patients with Parkinson’s disease: clinical practice versus clinical trials

✍ Scribed by Maurits E. L. Arbouw; Kris L. L. Movig; Henk-Jan Guchelaar; Petra J. E. Poels; Jeroen P. P. van Vugt; Cees Neef; Toine C. G. Egberts

Publisher: Springer
Year: 2008
Tongue: English
Weight: 149 KB
Volume: 64
Category: Article
ISSN: 0031-6970
DOI: 10.1007/s00228-008-0518-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical studies with ropinirole in Park

Clinical studies with ropinirole in Parkinson’s disease and RLS

✍ Wolfgang H. Jost; Dieter Angersbach; Olivier Rascol 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 225 KB

An open-label, multicentre clinical tria

An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease

✍ M. M. Pinter; A. W. F. Rutgers; E. Hebenstreit; on behalf of the the study cente 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 198 KB

S-adenosyl-methionine improves depressio

S-adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial

✍ Alessandro Di Rocco; John D. Rogers; Richard Brown; Peter Werner; Teodoro Bottig 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB 👁 2 views

Adalimumab safety in global clinical tri

Adalimumab safety in global clinical trials of patients with Crohn's disease

✍ Jean-Frédéric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr

Lack of pharmacokinetic interaction betw

Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease

✍ C. Thalamas; A. Taylor; C. Brefel-Courbon; S. Eagle; K. Fitzpatrick; O. Rascol 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 95 KB

Clinical and pharmacogenetic determinant

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease

✍ Maurits E. L. Arbouw; Kris L. L. Movig; Toine C. G. Egberts; Petra J. E. Poels; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 117 KB